Participant characteristics and partitioning per the clinical chemistry score (range 0 to 5 points) at presentation to the emergency department for all cohorts, by tests for cardiac troponin I or T*
| Characteristic | Score 0 | Score 1 | Score 2 | Score 3 | Score 4 | Score 5 |
|---|---|---|---|---|---|---|
| Hamilton cohort | ||||||
| hs-cTnI test | ||||||
| No. of participants | 91 | 208 | 264 | 264 | 146 | 119 |
| Age, median (IQR); yr | 44 (33–53) | 55 (46–63) | 69 (58–80) | 76 (64–83) | 78 (64–86) | 78 (70–86) |
| No. (%) of male participants | 43 (47.3) | 109 (52.4) | 117 (44.3) | 115 (43.6) | 70 (4847.9) | 61 (51.3) |
| hs-cTnI, median (IQR); ng/L | 1 (<1–2) | 2 (1–3) | 3 (2–6) | 8 (5–12) | 26 (19–48) | 67 (40–169) |
| Glucose, median (IQR); mmol/L | 5.1 (4.9–5.3) | 5.8 (5.2–6.6) | 6.1 (5.5–7.2) | 6.7 (5.8–8.7) | 6.4 (5.6–8.2) | 8.2 (6.7–11.4) |
| eGFR, median (IQR); mL/min/1.73 m2 | 101 (96–112) | 94 (86–103) | 77 (61–86) | 68 (46–80) | 58 (34–77) | 47 (30–66) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 2 (1.0) | 10 (3.8) | 35 (13.3) | 51 (34.9) | 79 (66.4) |
| hs-cTnT test | ||||||
| No. of participants | 88 | 193 | 229 | 228 | 182 | 172 |
| Age, median (IQR); yr | 44 (34–54) | 54 (45–62) | 64 (56–76) | 75 (63–83) | 80 (68–86) | 79 (70–86) |
| No. (%) of male participants | 41 (46.6) | 101 (52.3) | 101 (44.1) | 114 (50.0) | 83 (45.6) | 95 (55.2) |
| hs-cTnT, median (IQR); ng/L | 4 (<3–5) | 5 (< 3–7) | 8 (5–12) | 13 (10–16) | 28 (23–49) | 56 (39–96) |
| Glucose, median (IQR); mmol/L | 5.1 (4.9–5.3) | 5.7 (5.1–6.6) | 6.1 (5.5–7.8) | 6.8 (5.8–8.4) | 5.9 (5.4–7.7) | 7.7 (5.6–10.3) |
| eGFR, median (IQR); mL/min/1.73 m2 | 101 (96–110) | 94 (87–103) | 81 (69–89) | 69 (53–81) | 60 (40–77) | 44 (27–65) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 2 (1.0) | 10 (4.4) | 29 (12.7) | 52 (28.6) | 84 (48.8) |
| Brisbane cohort | ||||||
| hs-cTnI test | ||||||
| No. of participants | 147 | 260 | 175 | 127 | 45 | 41 |
| Age, median (IQR); yr | 46 (38–52) | 50 (41–59) | 57 (47–66) | 64 (54–77) | 72 (55–82) | 76 (65–83) |
| No. (%) of male participants | 77 (52.4) | 158 (60.8) | 111 (63.4) | 81 (63.8) | 25 (55.6) | 24 (58.5) |
| hs-cTnI, median (IQR); ng/L | 2 (2–2) | 2 (2–3) | 4 (3–5) | 6 (4–12) | 30 (18–83) | 130 (52–273) |
| Glucose, median (IQR); mmol/L | 5.2 (4.9–5.3) | 5.7 (5.2–6.4) | 6.1 (5.6–7.2) | 6.4 (5.7–8.0) | 6.3 (5.6–8.3) | 8.0 (6.6–9.2) |
| eGFR, median (IQR); mL/min/1.73 m2 | 104 (97–112) | 99 (91–107) | 84 (72–95) | 74 (57–86) | 70 (42–70) | 60 (42–74) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 0 (0) | 1 (0.6) | 9 (7.1) | 13 (28.9) | 26 (63.4) |
| hs-cTnT test | ||||||
| No. of participants | 162 | 250 | 176 | 108 | 53 | 46 |
| Age, median (IQR); yr | 46 (38–52) | 49 (40–57) | 58 (49–66) | 65 (57–74) | 76 (61–80) | 79 (67–84) |
| No. (%) of male participants | 84 (51.9) | 161 (64.4) | 106 (60.2) | 69 (63.9) | 28 (52.8) | 28 (60.9) |
| hs-cTnT, median (IQR); ng/L | 4 (3–5) | 5 (4–7) | 8 (6–11) | 12 (9–17) | 28 (22–40) | 69 (45–134) |
| Glucose, median (IQR); mmol/L | 5.1 (4.9–5.3) | 5.8 (5.3–6.4) | 6.1 (5.4–7.1) | 6.6 (5.9–8.0) | 6.7 (5.6–9.0) | 7.6 (6.5–8.5) |
| eGFR, median (IQR); mL/min/1.73 m2 | 104 (97–112) | 100 (92–108) | 84 (73–92) | 73 (61–84) | 64 (43–78) | 55 (36–72) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 1 (0.4) | 5 (2.8) | 9 (8.3) | 9 (17.0) | 25 (54.4) |
| Christchurch cohort | ||||||
| hs-cTnI test | ||||||
| No. of participants | 32 | 154 | 266 | 220 | 132 | 142 |
| Age, median (IQR); yr | 50 (42–55) | 56 (50–63) | 62 (53–70) | 70 (60–79) | 71 (60–78) | 71 (62–80) |
| No. (%) of male participants | 25 (78.1) | 88 (57.1) | 137 (51.5) | 134 (60.9) | 87 (65.9) | 98 (69.0) |
| hs-cTnI median ng/L (IQR) | 2 (2–3) | 2 (2–3) | 3 (2–5) | 7 (5–11) | 28 (20–134) | 231 (75–1099) |
| Glucose median mmol/L (IQR) | 5.1 (5–5.4) | 5.3 (5.1–5.7) | 5.9 (5.3–6.7) | 6.5 (5.8–7.6) | 6.2 (5.5–7.6) | 7.1 (6.0–9.1) |
| eGFR median mL/min/1.73m2 (IQR) | 98 (93–105) | 85 (76–95) | 74 (64–81) | 67 (56–80) | 64 (49–79) | 63 (48–74) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 1 (0.6) | 2 (0.8) | 27 (12.3) | 68 (51.5) | 127 (89.4) |
| hs-cTnT test | ||||||
| No. of participants | 43 | 191 | 269 | 168 | 129 | 146 |
| Age, median (IQR); yr | 50 (45–58) | 57 (50–63) | 61 (54–69) | 73 (64–79) | 73 (61–80) | 73 (64–80) |
| No. (%) of male participants | 29 (67.4) | 114 (59.7) | 135 (50.2) | 104 (61.9) | 85 (65.9) | 102 (69.9) |
| hs-cTnT, median (IQR); ng/L | 3 (3–4) | 4 (3–6) | 5 (3–8) | 13 (10–16) | 30 (22–49) | 85 (47–223) |
| Glucose, median (IQR); mmol/L | 5.1 (4.9–5.3) | 5.3 (5.1–5.7) | 6.1 (5.6–7.1) | 6.6 (5.9–7.8) | 6.0 (5.4–7.4) | 7.0 (6.0–8.9) |
| eGFR, median (IQR); mL/min/1.73 m2 | 97 (93–104) | 83 (75–93) | 75 (67–82) | 64 (56–73) | 65 (48–81) | 60 (44–71) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 6 (3.1) | 8 (3.0) | 24 (14.3) | 75 (58.1) | 112 (76.7) |
| Hamburg cohort | ||||||
| hs-cTnI test | ||||||
| No. of participants | 108 | 225 | 347 | 404 | 153 | 175 |
| Age, median (IQR); yr | 43 (33–52) | 52 (43–62) | 62 (50–73) | 71 (61–77) | 72 (60–79) | 73 (64–79) |
| No. (%) of male participants | 60 (55.6) | 142 (63.1) | 211 (60.8) | 277 (68.6) | 104 (68.0) | 105 (60.0) |
| hs-cTnI, median (IQR); ng/L | 2 (2–3) | 2 (2–4) | 4 (2–8) | 8 (5–12) | 27 (19–114) | 172 (59–749) |
| Glucose, median (IQR); mmol/L | 5.1 (4.8–5.3) | 5.4 (5.0–5.8) | 5.8 (5.3–6.7) | 6.5 (5.9–7.9) | 6.1 (5.6–7.4) | 7.1 (6.1–9.6) |
| eGFR, median (IQR); mL/min/1.73 m2 | 103 (97–112) | 94 (86–105) | 80 (66–91) | 67 (53–82) | 60 (45–80) | 58 (39–72) |
| No. (%) of participants with MI or who died within 30 d | 0 (0) | 2 (0.9) | 20 (5.8) | 60 (14.9) | 68 (44.4) | 126 (72.0) |
| hs-cTnT test | ||||||
| No. of participants | 151 | 254 | 338 | 311 | 168 | 190 |
| Age, median (IQR); yr | 43 (34–54) | 52 (45–61) | 62 (51–72) | 73 (64–78) | 73 (62–79) | 75 (66–82) |
| No. (%) of male participants | 86 (57.0) | 160 (63.0) | 207 (61.2) | 209 (67.2) | 120 (71.4) | 117 (61.6) |
| hs-cTnT, median (IQR); ng/L | 4 (< 3–5) | 5 (< 3–6) | 7 (5–10) | 13 (10–17) | 28 (23–56) | 74 (41–188) |
| Glucose, median (IQR); mmol/L | 5.1 (4.8–5.3) | 5.6 (5.2–6.0) | 6.0 (5.5–6.9) | 6.5 (5.8–8.0) | 6.2 (5.6–7.7) | 7.2 (6.2–9.7) |
| eGFR, median (IQR); mL/min/1.73 m2 | 103 (96–112) | 94 (82–102) | 78 (65–87) | 67 (53–80) | 57 (43–77) | 51 (35–69) |
| No. (%) of participants with MI or who died within 30 d | 1 (0.7) | 10 (3.9) | 25 (7.4) | 49 (15.8) | 70 (41.7) | 121 (63.7) |
Note: eGFR = estimated glomerular filtration rate, hs-cTnI = high-sensitivity cardiac troponin I, hs-cTnT = high-sensitivity cardiac troponin T, IQR = interquartile range, MI = myocardial infarction.
↵* Values rounded to nearest whole number except for glucose.